PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Zoledronic acid - Osteoporosis
PAD Profile : Zoledronic acid - Osteoporosis
Keywords :
Zoledronate
Brand Names Include :
Aclasta
Traffic Light Status
Status 1 of 2.
Status :
Red
Formulations :
- Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 October 2025
Committee Recommendations
Date
Committee Name
Narrative
25 September 2009
Surrey Medicines Commissioners Group
Zoledronic acid (Aclasta) - To use only on the recommendation of a Consultant Rheumatologist or Geriatrician in patients with osteoporosis for whom a bisphosphonate is the most appropriate line of treatment and who are unsuitable for or unable to tolerate oral bisphosphonates for osteoporosis or who are unable to comply with them and for patients with fractures despite oral bisphosphonates. It should be administered only in a place with the required clinical governance systems in place (training of staff, IV administration protocols etc).
21 November 2019
Surrey Downs MOG
SDCCG LOCAL INFORMATION - Epsom & St Helier and the Surrey Downs CCG MOG have agreed an information sheet for GPs in relation to the assessment and management of fragility fracture patients on IV Zoledronic acid.
See SDCCG document below
Associated BNF Codes
06. Endocrine System
06.06.02. Bisphosphonates and other drugs